Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443429 | 1.00 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2LMNAGAAHPGD | |
| SCHEMBL21286468 | 0.86 | CA2 (0.43) | ALDH1A1SMN1; SMN2CA2POLB | |
| SCHEMBL31683771 | 0.85 | CA2 (0.38) | ALDH1A1CA2CA1TP53TSHR | |
| SCHEMBL13576867 | 0.83 | CA2 (0.37) | ALDH1A1SMN1; SMN2CA2CA1MMP1 | |
| SCHEMBL11649386 | 0.81 | CA2 (0.36) | ALDH1A1SMN1; SMN2CA2CA1MMP1 | |
| SCHEMBL21166799 | 0.81 | CA2 (0.36) | ALDH1A1SMN1; SMN2HPGDCA2POLB | |
| SCHEMBL11649038 | 0.81 | CA2 (0.36) | ALDH1A1SMN1; SMN2CA2CA1MMP1 | |
| SCHEMBL30471231 | 0.81 | CA2 (0.36) | ALDH1A1SMN1; SMN2CA2POLB | |
| SCHEMBL9341542 | 0.80 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2LMNAGAAHPGD | |
| SCHEMBL9805189 | 0.80 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2LMNAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032199-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XW LABORATORIES INC. (KY) | 2021-02-04 | — | — | US | claimed |
| US-10836714-B2 | Ketamine derivatives and compositions thereof | XW LABORATORIES INC. (KY) | 2020-11-17 | — | — | US | claimed |
| US-20200231540-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XW LABORATORIES INC. (KY) | 2020-07-23 | — | — | US | claimed |
| US-10683262-B2 | Ketamine derivatives and compositions thereof | XW LABORATORIES INC. (KY) | 2020-06-16 | — | — | US | claimed |
| EP-4681777-A2 | PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2026-01-21 | — | — | EP | disclosed |
| EP-3737665-B1 | PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF | XWPHARMA LTD (KY) | 2026-01-07 | — | — | EP | disclosed |
| US-20250122149-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2025-04-17 | — | — | US | disclosed |
| US-12209060-B2 | Ketamine derivatives and compositions thereof | XWPharma Ltd. (KY) | 2025-01-28 | — | — | US | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-114805139-B | Prodrugs of ketamine, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20220411365-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2022-12-29 | — | — | US | disclosed |
| US-11440874-B2 | Ketamine derivatives and compositions thereof | XWPharma Ltd. (KY) | 2022-09-13 | — | — | US | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| US-4758623-A | Trifluoroacetylation of unhindered primary and secondary amines and polymer-bound trifluoroacetylation reagents | SCHERING CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| US-3985723-A | Trifluoroacetylation process | THE UNIVERSITY OF MISSISSIPPI (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209060-B2 | Ketamine derivatives and compositions thereof | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885SMN1; SMN2 581/4885LMNA 3314/4885 |
| US-20210032199-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885SMN1; SMN2 581/4885LMNA 3314/4885 |
| US-11440874-B2 | Ketamine derivatives and compositions thereof | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885SMN1; SMN2 581/4885LMNA 3314/4885 |
| US-10683262-B2 | Ketamine derivatives and compositions thereof | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885SMN1; SMN2 581/4885LMNA 3314/4885 |
| US-20200231540-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885SMN1; SMN2 581/4885LMNA 3314/4885 |
| US-20250122149-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885SMN1; SMN2 581/4885LMNA 3314/4885 |
| US-20220411365-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885SMN1; SMN2 581/4885LMNA 3314/4885 |
| US-10836714-B2 | Ketamine derivatives and compositions thereof | OPRK1, KCNK10, KCNK17 | ALDH1A1 2003/4885SMN1; SMN2 581/4885LMNA 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.